Last updated on January 2019

ValEAR


Brief description of study

To determine if treatment of cCMV-infected hearing impaired infants with isolated hearing loss with the antiviral drug valganciclovir reduces the maximum worsening in left or right ear hearing 8 months after randomization compared to untreated cCMV-infected hearing impaired infants

 

Clinical Study Identifier: TX217869

Contact Investigators or Research Sites near you

Start Over

Northwell Health Clinical Trials Office

Lake Success, New York United States
8.9miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.